Alithea Genomics Lands $8.9 Million in Seed Round
Alithea Genomics, a company based in Lausanne, Switzerland, specializing in large-scale RNA sequencing solutions, has successfully closed a seed funding round, raising $8.9 million. This investment aims to enhance the company's capabilities in generating big RNA data efficiently and cost-effectively from a variety of sample types.
Investors and Leadership Changes
The seed funding round was led by Genku Ventures, with participation from Novalis Biotech and Zürcher Kantonalbank. Alongside the funding announcement, Alithea Genomics has made notable changes in its leadership team. Frederik Decouttere, previously the company's chairman, has been appointed as the Chief Executive Officer. Co-founder Riccardo Dainese will now serve as Chief Commercial Officer, focusing on business development and commercialization efforts. Meanwhile, board member Kaspar Binz will take over as chairman.
Company Background
Founded in 2020 at EPFL in Lausanne, Alithea Genomics develops innovative RNA-seq technologies, such as BRB-seq and DRUG-seq, which allow researchers to assess gene expression by sequencing RNA. This technology is particularly useful in identifying active genes under certain conditions, including disease states or drug exposure, providing valuable insights for drug discovery.
Use of Funds
The newly acquired funds will be directed towards multiple strategic objectives. Alithea Genomics plans to accelerate the commercialization of its 1,536-well MERCURIUS™ DRUG-seq kits. These kits are designed to enable industrial-scale RNA sequencing, which is essential for primary drug screening and toxicology research. The technology allows for the simultaneous processing of up to 1,536 RNA samples, significantly enhancing throughput while reducing costs associated with traditional RNA sequencing methods.
Additionally, Alithea Genomics intends to invest in further development of its technologies and the creation of proprietary transcriptomic datasets. These datasets are expected to be instrumental in training AI and machine learning models for drug discovery and predictive biological research.
Future Prospects
With the support of its investors and the strategic use of its new funding, Alithea Genomics is well-positioned to advance its RNA sequencing solutions. This development marks a significant step forward in making large-scale transcriptomic data generation more accessible to pharmaceutical and biotechnology companies.